Clinical Trials Directory

Trials / Completed

CompletedNCT02231190

GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage

A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblinded) Study to Investigate Protective Effects of GSK1278863 on Eccentric Exercise Induced Muscle Damage in Healthy Male Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
26 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
Male
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

As per non-clinical studies, prolyl hydroxylase inhibitor GSK1278863 can protect muscle from unaccustomed exercise induced muscle damage and enhance functional muscle repair. This study is designed to investigate arm function, pain and other pharmacodynamic (PD) markers after unaccustomed maximal eccentric exercise with concurrent administration of GSK1278863 or placebo. Primary objective of the study is to evaluate the protective effects of GSK1278863 on eccentric exercise induced muscle injury. Subjects will be randomized in a 1:1 ratio (1 subject on GSK1278863 for every 1 subject on placebo). Each subject will be given five oral doses of GSK1278863/placebo in total. The first dose will be administered immediately after completion of eccentric exercise and then 4, 8, 24, and 48 hours later. Subjects will be housed till day 4 in unit and will return for a follow-up visit 7-10 days after discharge. After enrolment of approximately 30 subjects, enrolment will be paused and planned interim analysis will be performed to decide whether to terminate enrolment/study, continue dosing or to reduce the dose to 5 milligrams (mg).

Conditions

Interventions

TypeNameDescription
DRUGGSK1278863GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
DRUGPlaceboGSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise

Timeline

Start date
2015-01-15
Primary completion
2015-06-12
Completion
2015-06-12
First posted
2014-09-04
Last updated
2017-05-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02231190. Inclusion in this directory is not an endorsement.